Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER
Lawrence Livermore National Laboratory Livermore, CA 94550
SPONSORING I MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

SPONSOR/MONITOR'S REPORT
NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACT
Prostate cancer is the second leading cause of cancer death in men in the United States. A few epidemiology studies have indicated that exposure to PhIP, a rodent prostate carcinogen formed in meat during cooking, may be an important risk factor for prostate cancer in humans. Therefore, a highly sensitive biomarker assay is urgently needed to clarify the role of PhIP in prostate cancer. The goal of this project is to develop an assay that can be used to more accurately quantify human exposure to PhIP and potential prostate cancer risk. Our hypothesis is that an Accelerator Mass Spectrometry-based method can be developed to measure protein adducts of PhIP in the blood of humans. This will provide a measure of the internal dose, as well as the capacity for carcinogen bioactivation to a form that can initiate the cancer process. Towards this goal, we have characterized an adduct formed by PhIP in vitro with the amino acid cysteine. This adduct should provide a biomarker of dietary PhIP exposure and potential prostate cancer risk that could be used to identify individuals for prevention and for monitoring the effect of chemoprevention strategies.
SUBJECT TERMS
Protein adduct, PhIP, biomarker, prostate cancer, Accelerator mass Spectrometry The goal of this project is to develop an assay that can be used to more accurately quantify human exposure to PhIP and potential prostate cancer risk. Our hypothesis is that an Accelerator Mass Spectrometry-based method can be developed to measure protein adducts of PhIP in the blood of humans. This will provide a measure of the internal dose, as well as the capacity for carcinogen bioactivation to a form that can initiate the cancer process. In a proof-of-principle study, we will use the assay to investigate the hypothesis that African-Americans may be at greater risk for prostate cancer than Whites because they have adduct levels that are 2-3 fold higher in childhood.
Our aims are to 1) Characterize the protein adducts formed by PhIP with the blood protein albumin. 2) Develop an ultrasensitive radiommunoassay for PhIP albumin adducts so that they can be assessed in populations of people. 3) Measure PhIP-albumin adduct levels in blood samples obtained from African-American and White male children.
During the second year of this grant (February 1, 2004 to January 31, 2005 we have continued to work on specific aim 1 of the proposal. In the first year we identified a cysteine adduct that was formed between N-acetoxy PhIP and a peptide, however prior to raising antibodies against this adduct, it is crucial that we establish if the adduct is formed in albumin in vitro, as well as with albumin in vivo. This task has required considerably more effort than anticipated due to the low levels of adducts formed in vitro with N-acetoxy-PhIP. The progress is described as follows:
Specific aim #1: Characterize the adductsformed with the blood protein albumin after exposure to PhIP. The goal of this aim is to use in vitro methods to synthesize sufficient quantities of adducts for characterization by mass spectrometry and then establish if these adducts are formed in vivo in an animal model and humans.
Towards this goal, we have used 2 strategies to identify the adducts formed by PhIP. Firstly, we refined our methodology for cleaving adducts from proteins using acid hydrolysis. Heterocyclic amine adducts with a sulfur linkage to cysteine are cleaved by acid hydrolysis (Turesky et al., 1987) . Hence by treating the albumin samples with acid, recovering [ 14 C]PhIP through organic extraction and then analyzing using accelerator mass spectrometry (AMS), we can quantify the amount of the cysteine adduct formed in the rat and human plasma samples. Secondly, we have used 'traditional' mass spectrometry techniques to characterize other unknown albumin adducts formed in vitro and in vivo following exposure to unlabeled PhIP, deuterated PhIP and Nacetoxy PhIP.
Quantitation of cysteine adducts in human and rat albumin using acid hydrolysis and AMS:
We investigated the effect of hydrolysis time, temperature and pH on acid hydrolysis efficiency. We concluded that 24hr is sufficient in achieving a complete or near complete hydrolysis of the acid labile bonds. Unexpectedly, 12M and 6M HCl acid treatments resulted in less than 6% recovery of PhIP while IM, 0.1M and 0.01M HCl treatment resulted a consistent 17.4-18.1% recovery.
The methodology was then used to establish the percentage of PhIP-cysteine adduct in human and rat albumin samples. Twelve F344 male rats were gavaged either with corn oil only (controls) or 83.7mg PhIP in corn oil/kg body weight (dosed). Blood samples collected from the sacrificed rats were centrifuged at 3,000xg for 1 0min to obtain plasma. All samples are stored at -35°C until use. Albumin was isolated from the plasma as described in Dingley et al., 1999 . Human albumin was isolated from the blood of two human subjects that had been administered 1 ptg/kg body-weight 14 C-PhIP. Samples were obtained both 8hr and 24hr post-PhIP exposure.
Our data shows a slightly higher level of acid labile adducts in rats, ranging from 20-34%, than in humans, where the acid labile adduct level ranged between 15-41% in the Albumin of 8hr samples and 8% in 24hr samples.
Characterization of PhIP-albumin adducts using mass spectrometry:
Albumin that had been modified with N-acetoxy PhIP and deuterated N-acetoxy PhIP in vitro, as well as albumin from rats dosed with PhIP, were analyzed by mass spectrometry to identify targets for modification.
All albumin samples were desalted and digested using Trypsin and Glu-C endopeptidases, following standard procedures. Each set of peptide digestion consists of 4 samples: 2 control aliquots of unmodified albumin and 2 adduct aliquots of albumin-PHIP; one control and one adduct for trypsin digestion, the others for Glu-C digestion. Then all digested samples were completely dried using a speed vac.
Prior to injection into the mass spectrometer, they were re-dissolved (-10 pmol/VL) in 90% buffer A, 10% buffer B (buffer A: 10 mM ammonium acetate, buffer B: 90% acetonitrile and 0.1% formic acid; they are for nano-LC system). Data were collected on an FT-ICR mass spectrometer (Bruker Daltonics, MA) operated in the positive ion mode. The ionization source was operated under normal spray conditions with total flow rates of 100 nL/min. of nanospray. Typical conditions included a spray voltage of approximately 2 kV and a drying gas capillary temperature of 350 °C. Each dataset consisted of 400 experiments of 8 scans/experiment with a duty cycle time of 6 sec/experiment.
Bruker Xmass software was used to control the mass spectrometer. Software used for data analysis was provided by Dr. Gary H. Kruppa, Vice President of Bruker, Inc. The flow chart of experimental and analytical methods is shown in Figure 1 . Data collected on the control samples were compared to in silica digested albumin (from the protein database at Swiss-Prot/TrEMBL, www. expasy.org) to validate the peptide digestion and mass spectrometric methods. To be eligible, the experimental mass list should recover at least 95% fragments shown in that of in silica data. Next, data collected on the adducts were compared to in silica digested albumin with the addition of the mass of PhIP molecule and Am < 0.15. The adduct fragments were selected if their mass does not coexist with those of the control. Finally, the putative albumin-PhIP adduct fragments were validated by their presence in both the Tryptic-and the Glu-C-digested adduct samp'les.
a) Human serum albumin (HSA) reacted with N-acetoxy PhIP
The mass list for tryptic-digested HSA-PhIP sample displayed 2,799 values, among which 6 lead fragments were identified. Similarly, 6 lead fragments were found from the 4,312 mass values listed for Glu-C-digested HSA-PhIP sample. These putative peptide fragments are shown in Table 1 . Comparison of the tryptic-digested lead fragments with those of Glu-C-digested yielded the unique adduct fragment of TYVPK (residues 520-524 at the N-terminal of HSA sequence). The adduction in this sample was carried out with HSA and a mixture of N-Acetoxy-PhIP and N-Acetoxy-PhIP-D3 (about 1: 1 by weight). In addition, there were 2 separate samples incubated in 2h and 24h to assess the correlation between adduction level and incubation time.
Due to the presence of both regular and deuterated PhIP, analysis of this type of sample was conducted differently than it was for the regular ones. The fragment leads in each enzymedigested sample were selected according to the criteria: (1) Am <0.15 for the experimental mass relative to the in silica one, (2) Am = 3.0186 for the peptide mass of the adduct containing PhIP-D3 relative to that with regular PhIP, (3) co-elution or close elution time between the fragment containing PhIP-D3 relative to that with regular PhIP, (4) the same isotopic pattern or multiplicity for signals containing PhIP-D3 relative to that with regular PhIP.
Data on the in vitro HSA-PhIP(D:H) sample with 24h incubation time yielded 3,432 fragment masses, 8 of which met criteria (1) and (2). Two out of 8 candidates satisfied criterium (3) on the elution time. But none of them have the same isotopic pattern. Hence, no adduct fragment was selected for this sample.
Data on the in vitro HSA-PhIP(D:H) sample with 2h incubation time gave 1,233 peptide masses, among which 4 met criteria (1) and (2). Only 1 of these 4 candidates made to condition (4). Figure 4 depicts the similarity in isotopic pattern for the adduct signals of HSA-PhIP(H3) (top) and HSA-PhIP(D3) (bottom) of the peptide fragment AACLLPK (sequence position 199-205). However, their elution times are about 1.5 min. apart from each other. And due to the stronger hydrophobicity of deuterium relative to proton, it was unexpected that the deuterated fragment eluted before the corresponding protonated fragment. Thus, no fragment could be selected. However, this discussion is based only on the tryptic-digested sample. Data on the Glu-C digested in vitro HSA-PhIP(D:H) will be done and discussed.
It should be noted that the spectrometer was so sensitive in terms of being able to reflect the 3-fold peak intensity of the adduct fragment containing PhIP(D3) relative to that with regular PhIP (which is 3.0186 unit mass tower than its deuterated correspondent). Also it should be noted that the fragment leads yielded from these two samples of the in vitro HSA-PhIP(D:H) were not identical, although they underwent the adduction and later the enzymatic digestion in the same conditions, at the same time, with only different incubation times.
c) Rat serum albumin from animals dosed with [4C]PhIP
Of the 7,354 mass values from data on the tryptic-digested RSA-PhIP(' 4 C), 10 fragment leads were identified. Similarly, 9 leads were found from 3,932 mass values for data on the Glu-Cdigested RSA-PhIP(' 4 C). All the leads are listed in Table 3 . Combination of the leads in both tryptic-and Glu-C-digested data resulted in the following adduct fragments: Sequence Position SEIAHR [29] [30] [31] [32] [33] [34] According to the molecular simulated structure of RSA based on crystal structure of HSA, all the Cysteine residues in the above sequences are involved in disulfide bonds. Unless these bonds are broken, the sulfhydryl group in these Cysteines cannot bind the PhIP molecule. Also these results suggested that beside Cysteine (C), Methionine (M), Tyrosine (Y), Tryptophan (W) as indicated in the literature, 2 -5 PhIP possibly binds to other electron-rich side chain residues such as Glutamate (E), Aspartate (D), Lysine (K), Arginine (R), Serine (S), Threonine (T).
Discussion:
An overview of all the work discussed above suggests that the nanoLC nanospray FTMS is sufficiently sensitive to search for very low level of PhIP adducts in proteins. Also the adducts formed between PhIP and Cysteine are just one of the products and PhIP may bind to other amino acid residues as well.
Results deduced from in vitro HSA-PhIP and in vivo RSA-PhIP do not confirm the binding of PhIP to the only Cysteine with the free sulhydryl group in this protein. Crystal structure of HSA shows that the sulfhydryl side chain of this Cysteine is toward the interior of the protein, preventing it from readily coupling with the external ligand. 7 The most sensitive mass spectrometer has been used for this study. Considering the peptide-PhIP sample as an external standard, this spectrometer proved its ability to detect adducts at very low levels. So, if albumin-PhIP adducts were formed, this mass spectrometric system should succeed in picking up the adducts. Another proof of the sensitivity of this instrument is the variety of adduct fragments yielded from the high dose in vivo shown in the Results section, and their absence from the impure sample of in vivo HSA-PhIP(1 4 C). Also an evidence of the instrumental sensitivity is the 3-fold more intense of the peptide signal containing PhIP-D3 compared to its corresponding with regular PhIP (Figure 4 ) in the mass spectrum for in vivo HSA-PhIP(D:H).
However, the work on protein-PhIP adducts has still been inconclusive, in terms of the effective binding of PhIP to serum albumin. Current results suggest the presence of multiple protein-PhIP adducts and it seems that PhIP non-specifically binds to a variety of residual side chains at different locations. The difference in fragment leads found in the 2 samples of in vivo HSAPhIP(D:H), which only differ from each other by the incubation time, speaks strongly for the random binding of PhIP on serum albumin. In addition, although data on Glu-C-digested in vivo HSA-PhIP(D:H) have not been completed, the spreading of PhIP and PhIP-D3 on the trypticdigested sample and the absence of a specific binding site, where both fragment signals containing PhIP and PhIP(D3) coexist, also suggest the non-specific binding of PhIP to serum albumin.
Key Research Accomplishments:
During the second year of this grant, we have shown that: * Data indicates that the cysteine adduct is formed in vivo in rats and humans exposed to PhIP.
The level of these adducts is higher in rats than humans.
• The adducts formed between PhIP and Cysteine are just one of the products and PhIP may bind to other amino acid residues as well. 
